Extended indication Extension of indication to include treatment of paediatric patients from 6 kg to less than 25 kg.
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Dolutegravir/ abacavir /lamivudine
Domain Infectious diseases
Reason of inclusion Indication extension
Main indication Viral infections other
Extended indication Extension of indication to include treatment of paediatric patients from 6 kg to less than 25 kg.
Manufacturer ViiV

Registration

Submission date October 2023
Expected Registration August 2024
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.